HomeIMM • ASX
add
Immutep Ltd
Previous close
$0.31
Day range
$0.30 - $0.32
Year range
$0.23 - $0.46
Market cap
479.94M AUD
Avg Volume
3.92M
P/E ratio
-
Dividend yield
-
Primary exchange
ASX
In the news
Financials
Income Statement
Revenue
Net income
| (AUD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 865.57K | -4.89% |
Operating expense | 2.03M | -10.92% |
Net income | -10.74M | -11.49% |
Net profit margin | -1.24K | -17.23% |
Earnings per share | — | — |
EBITDA | -11.21M | -17.52% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (AUD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 181.88M | 47.37% |
Total assets | 201.58M | 36.71% |
Total liabilities | 12.06M | 9.82% |
Total equity | 189.52M | — |
Shares outstanding | 1.45B | — |
Price to book | 2.38 | — |
Return on assets | -14.53% | — |
Return on capital | -15.32% | — |
Cash Flow
Net change in cash
| (AUD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -10.74M | -11.49% |
Cash from operations | -8.19M | 30.16% |
Cash from investing | -10.30M | -87,445.92% |
Cash from financing | 47.81M | 25.58% |
Net change in cash | 29.03M | 5.47% |
Free cash flow | -6.10M | -44.31% |
About
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
CEO
Founded
2001
Website
Employees
19
